DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dyslexia — screening already-approved drugs against its 22-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDyslexia maps to a 22-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dyslexia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
StAR related lipid transfer domain containing 3 (STARD3) — STARD3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet +drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I9J · 1.74 Å · ligand L(+)-TARTARIC ACID (TLA). Experimental structure, not a prediction.
What the evidence adds up to
A 1997 study of visual processing in dyslexia found that the condition is not homogeneous. Approximately 75% of dyslexics have a processing deficit in the magnocellular pathway. The study examined three subtypes: dyseidetic, dysphonetic, and dysphoneidetic. Dyseidetic dyslexics did not have a magnocellular pathway defect, while dysphoneidetics did. Among dysphonetic dyslexics, the more severely affected subjects also exhibited a magnocellular pathway defect. The authors concluded that treatment strategies may need to be modified according to subtype.
A 1986 review of controlled studies using intensive teaching intervention for dyslexics reported that only one of eight studies showed the superiority of teaching over other methods. The same review examined work on the nootropic drug piracetam. It stated that piracetam lacked significant or serious adverse effects and appeared to improve memory and learning. Many double-blind studies of piracetam in dyslexic children suggested that piracetam improves reading ability, and electrophysiological studies supported the notion that piracetam may be left-hemisphere active. No later controlled trials confirming or refuting these findings were provided in the abstracts.
A 2020 chapter on neuropsychological treatment of dyslexia in clinical practice discussed the difficulty of translating scientific theories into applied treatment. It described a study in which neuropsychological treatment was applied to dyslexic children in an outpatient setting, and presented preliminary results of an intervention and follow-up. No specific outcomes, sample sizes, or comparative data were given.
What is still missing are large, independently replicated, placebo-controlled trials of piracetam in well-characterised dyslexic subtypes, with long-term follow-up of reading outcomes. The 1997 visual-processing findings have not been linked to any drug treatment in the abstracts provided. No trial has tested whether subtype-specific magnocellular deficits predict differential response to any intervention. Funding for such stratified trials, and a standardised diagnostic framework for dyslexia subtypes, remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Optometry and Vision Science · 1997 · 48 citations
Not All Dyslexics Are Created Equal
AbstractBACKGROUND: Dyslexia is a common disorder that has traditionally been treated as a homogeneous condition. However, recent evidence indicates that it is a heterogenous condition with several subtypes. For example, studies of the visual system indicate that not all dyslexics have a normal visual pathway. Approximately 75% have a processing deficit in the magnocellular pathway. Our previous study indicated that dysphoneidetic but not dyseidetic dyslexics exhibit a magnocellular pathway defect. PURPOSE: The purpose of this study was to expand our previous work by also examining dysphonetic dyslexics. Additionally, the stimulus was altered to enhance detection of a magnocellular pathway defect in any dyslexic subtype. METHODS: Temporal contrast sensitivity functions were determined with a flickering stimulus (5, 10, 15, 20, and 25 Hz) by using a temporal, two-alternative, forced-choice technique. RESULTS: The results indicate that the dyseidetic dyslexics do not have a magnocellular pathway defect, whereas the dysphoneidetics do. Furthermore, examination of the individual dysphonetics indicated that the more severely affected subjects also exhibited a magnocellular pathway defect. CONCLUSION: These results suggest that treatment strategies for dyslexics may need to be modified to take into account their specific subtype.
Neuropsychological Treatment of Dyslexia in Clinical Practice
AbstractThis chapter discusses the problems of translating scientific theories on dyslexia into applied treatment. The importance of a thorough diagnostic examination and a clear procedure in selecting treatment methods is indicated. Next, a study is described in which neuropsychological treatment of dyslexic children is applied in an out-patient setting. Preliminary results of an intervention and follow-up are presented.
Early Child Development and Care · 1986 · 1 citations
Developmental dyslexia and the nootropic concept†
AbstractA review is presented of controlled studies using intensive teaching intervention to improve dyslexics’ reading ability. The results of eight such studies reveal only one showing the superiority of teaching over other methods. With this background, the work on nootropics is reviewed. Both animal and clinical work with piracetam #opthe first of the nootropics#cp seems to indicate that this medication lacks significant or serious adverse effects and appears to improve memory and learning. Many double-blind studies of piracetam have now been conducted on dyslexic children, which suggest that piracetam improves their reading ability. In addition electrophysiological studies support the notion that piracetam may be “left hemisphere active.”
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
